FGP
ZBIO

Freestone Grove Partners’s Zenas BioPharma ZBIO Stock Holding History

Freestone Grove Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25 Buy
+1
New +$20 ﹤0.01% 958

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Freestone Grove Partners's ZBIO Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 1 share worth $25. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings.

145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Freestone Grove Partners held 1 share of Zenas BioPharma worth $25 as of Q2 2026.
  • Zenas BioPharma was a new Freestone Grove Partners position in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #958 holding.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.